BRITISH JOURNAL OF PHARMACOLOGY

The British Journal of Pharmacology welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

Edited for the British Pharmacological Society by

A.T. Birmingham (Chairman)

R.W. Horton W.A. Large (Secretaries)

Editorial Board

P.I. Aaronson London J.A. Angus Melbourne, Australia G.W. Bennett Nottingham T.P. Blackburn Harlow N.G. Bowery London W.C. Bowman Glasgow S.D. Brain London K.D. Butler Horsham M. Caulfield London R. Chess-Williams Sheffield T. Cocks Melbourne, Australia S.J. Coker Liverpool R.A. Coleman Ware Helen M. Cox London A.J. Cross London V. Crunelli Cardiff T.C. Cunnane Oxford F. Cunningham London A. Dickenson London J.R. Docherty Dublin A. Dray London L. Edvinsson Lund, Sweden G. Edwards Manchester J.M. Edwardson Cambridge R.M. Eglen Palo Alto, USA P.C. Emson Cambridge A.C. Foster San Diego, USA

J.P. Gallagher Galveston, USA Sheila M. Gardiner Nottingham C.J. Garland Bristol A. Gibson London M.A. Giembycz London W.R. Giles Calgary, Canada R.G. Goldie Perth, Australia R.J. Griffiths Connecticut, USA R.W. Gristwood Cambridge Judith M. Hall London D.W.P. Hay Philadelphia, USA P.G. Hellewell London P.E. Hicks Edinburgh S.J. Hill Nottingham K. Hillier Southampton S.M.O. Hourani Guildford J.C. Hunter Palo Alto, USA E.J. Johns Birmingham R.S.G. Jones Oxford C.C. Jordan Ware P.A.T. Kelly Edinburgh D.A. Kendall Nottingham C. Kennedy Glasgow P. Leff Loughborough A.T. McKnight Cambridge C.A. Maggi Florence, Italy Janice M. Marshall Birmingham G. Martin Beckenham

A. Mathie London D.N. Middlemiss Harlow P.K. Moore London C.D. Nicholson Oss. The Netherlands H. Osswald Tübingen, Germany F.L. Pearce London J.D. Pearson London A.G. Renwick Southampton P.J. Roberts Bristol G.J. Sanger Harlow W.C. Sessa Connecticut, USA P. Sneddon Glasgow K. Starke Freiburg, Germany R.J. Summers Melbourne, Australia P.V. Taberner Bristol J. Tamargo Madrid, Spain C. Thiemermann London M.D. Tricklebank Basle, Switzerland T.J. Verbeuren Suresnes, France R.R. Vollmer Pittsburgh, USA K.J. Watling Boston, USA A.H. Weston Manchester J. Westwick Bath Eileen Winslow Riom, France E.H.F. Wong Milan, Italy B. Woodward Bath

Corresponding Editors

W. Martin Glasgow

P.R. Adams Stony Brook, U.S.A.
C. Bell Dublin
F.E. Bloom La Jolla, U.S.A.
A.L.A. Boura Newcastle, Australia
N.J. Dun Toledo, U.S.A.
R.F. Furchgott New York, U.S.A.
T. Godfraind Brussels, Belgium
S.Z. Langer Paris, France

J.R. Fozard Basle, Switzerland

Allison D. Fryer Baltimore, USA

R.J. Miller Chicago, U.S.A.
R.C. Murphy Denver, U.S.A.
E. Muscholl Mainz, Germany
R.A. North Geneva, Switzerland
M. Otsuka Tokyo, Japan
M.J. Rand Melbourne, Australia
S. Rosell Södertalje, Sweden
P. Seeman Toronto, Canada

L. Szekeres Szeged, Hungary
B. Uvnas Stockholm, Sweden
P.A. Van Zwieten Amsterdam, Netherlands
V.M. Varagič Belgrade, Yugoslavia
G. Velo Verona, Italy
Wang Zhen Gang Beijing, China
M.B.H. Youdim Haifa, Israel

Submission of manuscripts: Manuscripts (two copies) should be sent to The Editorial Office, British Journal of Pharmacology, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE.

Authors should consult the Instructions to Authors and the Nomenclature Guidelines for Authors in Vol. 114, 245-255. These Instructions and Guidelines also appear with the journal Index for Volumes 111-113, 1994. A checklist of the essential requirements is summarised in each issue of the journal, or as the last page of the issue.

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they and the *British Pharmacological Society* wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the *British Pharmacological Society*, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

- K.M. Heygate, I.G. Lawrence, M.A. Bennett & H. Thurston. Impaired endothelium-dependent relaxation in isolated resistance arteries of spontaneously diabetic rats

 3251
- L.A. Dawson & C. Routledge. Differential effects of potassium channel blockers on extracellular concentrations of dopamine and 5-HT in the striatum of conscious rats

 3260
- **K.** Venkova & J. Krier. Postjunctional α_1 and β -adrenoceptor effects of noradrenaline on electrical slow waves and phasic contractions of cat colon circular muscle 3265
- K. Kinoshita, Y. Watanabe, H. Asai, M. Yamamura & Y. Matsuoka. Anti-ataxic effects of TRH and its analogue, TA-0910, in Rolling mouse Nagoya by metabolic normalization of the ventral tegmental area 3274
- L. Eriksen & C. Thomsen. [³H]-L-2-amino-4-phosphonobutyrate labels a metabotropic glutamate receptor, mGluR4a 3279
- D. Constantin-Teodosiu, P.L. Greenhaff, S.M. Gardiner, M.D. Randall, J.E. March & T. Bennett. Attenuation by creatine of myocardial metabolic stress in Brattleboro rats caused by chronic inhibition of nitric oxide synthase

 3288
- M. Martin-Caraballo, C.R. Triggle & D. Bieger. Photosensitization of oesophageal smooth muscle by 3-NO₂-1,4-dihydropyridines: evidence for two cyclic GMP-dependent effector pathways 3293
- **K.B. Mian & W. Martin.** The inhibitory effect of 3-amino-1,2,4-triazole on relaxation induced by hydroxylamine and sodium azide but not hydrogen peroxide or glyceryl trinitrate in rat aorta

 3302

- T. Hohlfeld, P. Klemm, C. Thiemermann, T.D. Warner, K. Schrör & J.R. Vane. The contribution of tumour necrosis factor- α and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin 3309
- Z. Fatehi-Hassanabad, B.L. Furman & J.R. Parratt. The effect of endotoxin on sympathetic responses in the rat isolated perfused mesenteric bed; involvement of nitric oxide and cyclo-oxygenase products

 3316
- J.S. Bedingfield, M.C. Kemp, D.E. Jane, H.-W. Tsu, P.J. Roberts & J.C. Watkins. Structure-activity relationships for a series of phenylglycine derivatives acting at metabotropic glutamate receptors (mGluRs)

 3323
- C.M. Villalón, J. Contreras, E. Ramírez-San Juan, C. Castillo, M. Perusquía & J.A. Terrón. Characterization of prejunctional 5-HT receptors mediating inhibition of sympathetic vasopressor responses in the pithed rat

 3330
- M. Vázquez, M. Alegret, M. López, C. Rodríguez, T. Adzet, M. Merlos & J.C. Laguna. Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guineapigs 3337

Erratum 3344

The British Journal of Pharmacology is published by Stockton Press, a division of Macmillan Press Ltd. It is the official publication of the British Pharmacological Society.

Scope The British Journal of Pharmacology is published twice a month. It welcomes contribution in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

This journal is covered by Current Contents, Excerpta Medica, BIOSIS, CABS, CINAHL and Index Medicus.

Editorial Manuscripts (plus two copies) and all editorial correspondence should be sent to: The Editorial Office, British Journal of Pharmacology, St George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, UK. Tel: +44 (0)181 767 6765; Fax: +44 (0)181 767 5645.

Advertisements Enquiries concerning advertisements should be addressed to: Michael Rowley, Hasler House, High Street, Great Dunmow, Essex CM6 1AP, UK. Tel: +44 (0)1371 874613; Fax: +44 (0)1371 872273.

Publisher All business correspondence, supplement enquiries and reprint requests should be addressed to British Journal of Pharmacology, Stockton Press, Houndmills, Basingstoke, Hampshire RG21 2XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526. Publisher: Marija Vukovojac. Production Controller: Nicci Crawley.

Subscriptions – EU/Rest of World Subscription price per annum (3 volumes, 24 issues) £665, rest of world £880 (Airmail), £735 (Surface mail) or equivalent in any other currency. Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Magazines and sent to: The Subscription Department Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Subscribers from EC territories should add sales tax at the local rate.

Subscriptions – USA USA subscribers call toll free 1-800-221-2123 or send check/money order/credit card details to: Stockton Press, 49, West 24th Street, New York, NY 10010; Tel: 212 627 5757, Fax: 212 627 9256. USA annual subscription rates: \$1400 Airmail; \$1170 Surface (Institutional/Corporate); \$240 (Individual making personal payment).

British Journal of Pharmacology (ISSN 0007-1188) is published twice a month by Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA. Subscription price for institutions is \$1400 per annum (surface). 2nd class postage is paid at Rahway NJ. Postmaster: send address corrections to Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel NJ 07001.

Reprints of any article in this journal are available from Stockton Press, Houndmills, Basingstoke, Hampshire RG21 2XS, UK.
Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526.

Copyright © 1995 Stockton Press ISSN 0007-1188

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Stockton Press for libraries and other users registered with the Copyright Clearance Center (CCC) Transaction Reporting Service, provided that the base fee of \$12.00 per copy is paid directly to CCC, 21 Congress St., Salem, MA 01970, USA. 0007 – 1188/95 \$12.00 + \$0.00.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency.

PREPARATION OF MANUSCRIPTS

Authors are strongly recommended to read the full Instructions to Authors and Nomenclature Guidelines for Authors (Br. J. Pharmacol. 1995, 114, 245-255) before submitting a manuscript for publication in the British Journal of Pharmacology. The manuscript and cover letter should be checked against the following list before mailing.

The original and one copy of the manuscript must be supplied. Manuscripts must be typed in double-line spacing on one side of A4 paper, in type not smaller than 12 characters per inch or 10 point. Both copies to include Tables and a set of labelled Figures. One set of Figures without numbers or letters is also to be included. The text to be arranged in the following subsections:

- 1. **Title**—To have no more than 150 characters on a separate page, which should also include a Short Title (50 characters maximum) and the name and address of the author for correspondence.
- Summary To be arranged in numbered paragraphs (Full Papers) or a single paragraph (Special Reports).
 —to include aims, principal results and conclusions.
 —to include Key words (10 maximum) at end of summary.
- 3. **Introduction**—To contain concise statements of the problem and the aims of the investigation.
- 4. **Methods**—To have brief but adequate account of the procedures; full names of drugs (including those referred to by manufacturer's code), sources of drugs and statistical tests to be stated.
- Results—To have no repetition of data in Figures, Tables and text.
- Discussion Findings and conclusions to be placed in context of other relevant work.
 NB Simple repetition of results and unwarranted speculation are not acceptable.
- Acknowledgements Sources of support. Sources of drugs not widely available commercially.
- References All references in the text to be included in the Reference List and vice versa. References in alphabetical order with complete citations; Journals publishing 'in press' papers identified.

- References to manuscripts submitted to other journals but not yet accepted are not allowed.
- 9. Tables—Each on a separate page and prepared in accordance with current requirements of the Journal.
- 10. Figures Both labelled and non-labelled Figures to be prepared in accordance with current requirements of the Journal (see *Instructions to Authors*, 1994, 114, 245-251) and provided with Figure Number and Authors' names on back (in pencil).
 - —each legend to be typed on a separate page and carrying keys to symbols.
 - —keys to symbols and histograms must not appear on the figures themselves, but in the respective legends.
 - —'box style' figures are not in keeping with the Journal style; line drawings etc must have only left-hand and bottom axes.
- 11. Manuscripts—To be accompanied by a declaration signed by each author that
 - (a) results are original
 - (b) approval of all persons concerned has been given to submit manuscripts for consideration (see also 12b)
 - (c) the same material is neither 'in press' (i.e. is in proof or has definitely been accepted for publication) nor under consideration elsewhere. Furthermore it will not be submitted or published elsewhere before a decision has been reached by the Editorial Board of the British Journal of Pharmacology and will not be submitted elsewhere if accepted by the British Journal of Pharmacology.
 - (d) Copyright assignment is included.
- 12. Cover letter—To state clearly
 - (a) Corresponding author's full postal address, telephone, telex or Fax number
 - (b) where appropriate, that *either* ethical approval has been given for investigation or Company or Institutional permission to publish work has been received.
- 13. **Reminder**—Packaging to be sufficiently robust to protect Figures and to withstand mailing.

Failure to comply with *Instructions to Authors* may lead to substantial delays in processing, review and publication and may even jeopardize acceptance of the manuscript.

NOMENCLATURE

Authors are reminded that accepted receptor and associated terminology is laid out in Nomenclature Guidelines for Authors, as published in the British Journal of Pharmacology, Br. J. Pharmacol., 1995, 114, 253-255.

SPECIAL REPORTS

The purpose of *Special Reports* is to provide rapid publication for **new** and **important** results which the Editorial Board considers are likely to be of special pharmacological significance. *Special Reports* will have publication priority over all other material and so authors are asked to consider carefully the status of their work before submission.

In order to speed publication there is normally no revision allowed beyond very minor typographical or grammatical corrections. If significant revision is required, the Board may either invite rapid re-submission or, more probably, propose that it be re-written as a Full Paper and be re-submitted for consideration. In order to reduce delays, proofs of *Special Reports* will be sent to authors but essential corrections must reach the Production Office within 48 hours of receipt. Authors should ensure that their submitted material conforms exactly to the following requirements.

Special Reports should normally occupy no more than two printed pages of the Journal; two illustrations (Figures or Tables, with legends) are permitted. As a guideline, with type face of 12 pitch and double-line spacing, a page of A4 paper could contain about 400 words. The absolute maximum length of the Special Report is 1700 words. For each Figure or Table, please deduct 200 words. The manuscript should comprise a Title page with key words (maximum of 10), a Summary consisting of a single short paragraph, followed by Introduction, Methods, Results, Discussion and References (maximum of 10). In all other respects, the requirements are the same as for Full Papers (see current 'Instructions to Authors').

SPECIAL REPORT

G.R. Drummond & T.M. Cocks. Endothelium-dependent relaxation to the B_1 kinin receptor agonist des-Arg⁹-bradykinin in human coronary arteries 3083

PAPERS

- J. Srinivasan, A. Richens & J.A. Davies. The effect of the desglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK-801) on endogenous amino acid release from mouse cortex

 3087
- D.E. McBean, V. Winters, A.D. Wilson, C.B. Oswald, B.J. Alps & J.M. Armstrong. Neuroprotective efficacy of lifarizine (RS-87476) in a simplified rat survival model of 2 vessel occlusion 3093
- R.A.D. Rutherford, A. McCarthy, M.H.F. Sullivan, M.G. Elder, J.M. Polak & J. Wharton. Nitric oxide synthase in human placenta and umbilical cord from normal, intrauterine growth-retarded and pre-eclamptic pregnancies 3099
- E. Butt, D. Pöhler, H.-G. Genieser, J.P. Huggins & B. Bucher. Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS 3110
- J. Peyroux, F. Beslot, N. Claperon, M.-C. Fournie-Zaluski & B.P. Roques. Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide 3117
- K. Varani, L. Beani, C. Bianchi, P.A. Borea & M. Simonato. Changes in $[^3H]$ -UK14304 binding to α_2 -adrenoceptors in morphine-dependent guinea-pigs 3125
- N. Takeshita & I. Yamaguchi. Meta-chlorophenylpiperazine attenuates formalin-induced nociceptive responses through 5- $HT_{1/2}$ receptors in both normal and diabetic mice 3133
- F.C. Halliday, P.I. Aaronson, A.M. Evans & A.M. Gurney. The pharmacological properties of K⁺ currents from rabbit isolated aortic smooth muscle cells

 3139
- D.T. Beattie, I.J.M. Beresford, H.E. Connor, F.H. Marshall, A.B. Hawcock, R.M. Hagan, J. Bowers, P.J. Birch & P. Ward. The pharmaceology of GR203040, a novel, potent and selective non-peptide tachykinin NK₁ receptor antagonist 3149
- C.J. Gardner, D.J. Twissell, T.J. Dale, J.D. Gale, C.C. Jordan, G.J. Kilpatrick, C. Bountra & P. Ward. The broad-spectrum antiemetic activity of the novel non-peptide tachykinin NK₁ receptor antagonist GR203040 3158
- J.M. Hall, M. Figini, S.K. Butt & P. Geppetti. Inhibition of bradykinin-evoked trigeminal nerve stimulation by the non-peptide bradykinin B_2 receptor antagonist WIN 64338 in vivo and in vitro 3164
- K.H. Banner, N.M. Roberts & C.P. Page. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis

 3169
- H. Thorlacius, J. Raud, X. Xie, P. Hedqvist & L. Lindbom. Microvascular mechanisms of histamine-induced potentiation of leukocyte adhesion evoked by chemoattractants 3175
- M.W. Bunting & R.E. Widdop. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT₁-receptor antagonists in spontaneously hypertensive rats 3181
- S.J. De Kimpe, C. Thiemermann & J.R. Vane. Role for intracellular platelet-activating factor in the circulatory failure in a model of Grampositive shock 3191
- F.M. Cutrer, V. Limmroth, G. Ayata & M.A. Moskowitz. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin 3199
- M.J. Barjavel, J.-M. Scherrmann & H.N. Bhargava. Relationship between morphine anaglesia and cortical extracellular fluid levels of morphine and its metabolites in the rat: a microdialysis study

 3205

- M.-H. Wu, M.-J. Su, S.-S. Lee, L.-T. Lin & M.-L. Young. Electrophysiological basis for antiarrhythmic efficacy, positive inotropy and low proarrhythmic potential of (-)-caryachine 3211
- A.G. Stewart, D. Fernandes & P.R. Tomlinson. The effect of glucocorticoids on proliferation of human cultured airway smooth muscle

 3219
- M. Umemiya & A.J. Berger. Inhibition by riluzole of glycinergic postsynaptic currents in rat hypoglossal motoneurones 3227
- E. Lilley & A. Gibson. Inhibition of relaxations to nitrergic stimulation of the mouse anococcygeus by duroquinone 3231
- P.H. Van der Graaf, P.R. Saxena, N.P. Shankley & J.W. Black. Exposure and characterization of the action of noradrenaline at dopamine receptors mediating endothelium-independent relaxation of rat isolated small mesenteric arteries 3237
- S.M. Wileman, G.E. Mann & A.R. Baydoun. Induction of L-arginine transport and nitric oxide synthase in vascular smooth muscle cells: synergistic actions of pro-inflammatory cytokines and bacterial lipopolysaccharide 3243
- K.M. Heygate, I.G. Lawrence, M.A. Bennett & H. Thurston. Impaired endothelium-dependent relaxation in isolated resistance arteries of spontaneously diabetic rats

 3251
- L.A. Dawson & C. Routledge. Differential effects of potassium channel blockers on extracellular concentrations of dopamine and 5-HT in the striatum of conscious rats

 3260
- **K.** Venkova & J. Krier. Postjunctional α_1 and β -adrenoceptor effects of noradrenaline on electrical slow waves and phasic contractions of cat colon circular muscle 3265
- K. Kinoshita, Y. Watanabe, H. Asai, M. Yamamura & Y. Matsuoka. Anti-ataxic effects of TRH and its analogue, TA-0910, in Rolling mouse Nagoya by metabolic normalization of the ventral tegmental area 3274
- L. Eriksen & C. Thomsen. [3H]-L-2-amino-4-phosphonobutyrate labels a metabotropic glutamate receptor, mGluR4a 3279
- D. Constantin-Teodosiu, P.L. Greenhaff, S.M. Gardiner, M.D. Randall, J.E. March & T. Bennett. Attenuation by creatine of myocardial metabolic stress in Brattleboro rats caused by chronic inhibition of nitric oxide synthase

 3288
- M. Martin-Caraballo, C.R. Triggle & D. Bieger. Photosensitization of oesophageal smooth muscle by 3-NO₂-1,4-dihydropyridines: evidence for two cyclic GMP-dependent effector pathways 3293
- **K.B. Mian & W. Martin.** The inhibitory effect of 3-amino-1,2,4-triazole on relaxation induced by hydroxylamine and sodium azide but not hydrogen peroxide or glyceryl trinitrate in rat aorta

 3302
- T. Hohlfeld, P. Klemm, C. Thiemermann, T.D. Warner, K. Schrör & J.R. Vane. The contribution of tumour necrosis factor- α and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin 3309
- Z. Fatehi-Hassanabad, B.L. Furman & J.R. Parratt. The effect of endotoxin on sympathetic responses in the rat isolated perfused mesenteric bed; involvement of nitric oxide and cyclo-oxygenase products

 3316
- J.S. Bedingfield, M.C. Kemp, D.E. Jame, H.-W. Tsu, P.J. Roberts & J.C. Watkins. Structure-activity relationships for a series of phenylglycine derivatives acting at metabotropic glutamate receptors (mGluRs)

 3323
- C.M. Villalón, J. Contreras, E. Ramírez-San Juan, C. Castillo, M. Perusquía & J.A. Terrón. Characterization of prejunctional 5-HT receptors mediating inhibition of sympathetic vasopressor responses in the pithed rat

 3330
- M. Vázquez, M. Alegret, M. López, C. Rodríguez, T. Adzet, M. Merlos & J.C. Laguna. Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guineapigs 3337

Erratum 3344

